Open Veils · Answer
Alternative treatment for LADA
LADA sits in an immunological no-man's land that standard T2D protocols actively harm. The suppressed clinical priority is immune preservation, not just glucose control. Sulfonylureas — still widely prescribed — are documented to accelerate beta-cell destruction in LADA. The more radical fringe holds that the autoimmune attack itself must be the primary therapeutic target, not glycemia.
Evidence
- LADA (Latent Autoimmune Diabetes in Adults) is mechanistically closer to slow-onset Type 1 than Type 2, driven by GAD-antibody-mediated autoimmune beta-cell destruction.
- On immune modulation: a Phase II clinical trial of BCG (Bacillus Calmette-Guérin) vaccine reported at the American Diabetes Association in June 2026 showed BCG was safe in LADA and produced a statistically significant improvement in insulin-dose adjusted A1c (IDAA1c), though raw HbA1c did not reach significance.
- On pharmacological beta-cell preservation: DPP-4 inhibitors (sitagliptin class) are flagged by integrative clinicians as underutilised — pilot and prospective studies suggest C-peptide preservation, particularly when combined with vitamin D supplementation, per the Cleveland Clinic Journal of Medicine (December 2025).
- Weston A. Price-aligned and functional medicine practitioners — including researchers associated with Jack Kruse's mitochondrial framework — point to chronic vitamin D insufficiency, leaky gut permitting molecular mimicry, and circadian disruption as upstream drivers of the autoimmune cascade in LADA.
- The alternative and integrative record clusters around three vectors: immune modulation, beta-cell preservation, and terrain medicine.
